Abstract
Synopsis: Despite clinical guidelines recommending triple therapy with an inhaled corticosteroid (ICS), long-acting muscarinic receptor antagonist (LAMA), and long-acting beta-agonist (LABA) for individuals with GOLD D chronic obstructive pulmonary disease, the evidence supporting this is weak. The IMPACT study was a randomized controlled trial that provided evidence that exacerbation risk is decreased in patients using triple therapy compared with an ICS/LABA or LAMA/LABA. Source: Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with chronic obstructive pulmonary disease. N Engl J Med 2018;378(18):1671–1680.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
